Kaposi Sarcoma Market Outlook, Top Key Players, Industry Growth Analysis and Forecast to 2022

More documents

Recommendations

Info

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market KS can cause serious problems or even become life treating when the lesions are in the lungs, liver, or in digestive tract. The means that the when KS occurs in someone is infected with HIV. Chemotherapy, immunotherapy, and antiretroviral therapy (HAART) are the key treatment methods for Kaposi sarcoma. The HAART therapy emerged as the leading segment owing to the high incidence of AIDS-related Kaposi sarcoma globally. HAART therapy includes the combination of reverse transcriptase (RT) inhibitors, fusion inhibitors, and protease inhibitors. Chemotherapy is likely to grow at the fastest pace during the forecast period due to the high cost of the treatment and the increasing adoption by immunocompentent patients. The leading chemotherapy drugs include paclitaxel, liposomal doxorubicin and daunorubicin, bleomicin and vincristine. Immunotherapy consists of interferon alfa; which is the first biological drug approved by the FDA to the treatment of Kaposi sarcoma. Patients with good immune functions show effectiveness. However, immune compromised patients rarely respond to this therapy. The therapy accounted for the least share in the global market. Kaposi Sarcoma Market by Type of Treatment is segmented into Chemotherapy, Liposomal Anthracyclines, Alkaloids, Immunotherapy, HAART. Kaposi Sarcoma Market by Distribution Channel is segmented into Hospitals, Cancer Research Institutes, Multispecialty Clinics, Ambulatory Surgical Centers. Request Sample Copy of this Market Research @ https://www.millioninsights.com/industry-reports/Kaposi-sarcoma-ks-market/request-sample Kaposi Sarcoma Market by Geographical Region is segmented into North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa. North America contributed to the major share in the Kaposi sarcoma market in 2015. Due to the presence of key market players and the increasing cost of drugs; the growth of the market is also driven by the easy availability of drugs and a high diagnosis rate of the malignancy. The high cost of the therapy is a deterrent to patients in developing regions such as Asia Pacific and the Middle East and Africa and this limits its adoption. A limited number of approved biologics is also a prominent factor restraining the growth of the immunotherapy segment. The Middle East and Africa are expected to expand at the highest CAGR during the forecast period owing to the high incidence and prevalence of KS in Eastern Africa. The trend is consistent with the geographic variations of the HIV/AIDS epidemic. The key players include Aphios Corporation, AstraZeneca Plc, Biogenomics Limited, and CytRx Corporation. Eli Lilly and Co.,
Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.). Market Segment: This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering • Merck • Johnson & Johnson • GlaxoSmithKline • Bristol-Myers Squibb • Eli Lilly and Pfizer By types, the market can be split into • HAART • Chemotherapy • Immunotherapy By Application, the market can be split into • Hospitals • Clinics • Other By Regions, this report covers (we can add the regions/countries as you want) • North America • China • Europe • Southeast Asia • Japan • India See More Reports of this Category by Million Insights @ https://www.millioninsights.com/industry/healthcare
Page 1: Kaposi Sarcoma Market Outlook, Top

Kaposi Sarcoma Market Outlook, Top Key Players, Industry Growth Analysis and Forecast to 2022

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?